Compass Therapeutics (NASDAQ: CMPX) announced that clinical data from its Phase 2/3 study of tovecimig in biliary tract cancer has been accepted for an oral presentation at the ESMO Congress. The company also reported its second-quarter financial results, highlighting a solid cash and marketable securities position of approximately $180 million, which is expected to support ongoing clinical operations and pipeline trials into 2028.